Glucose transporters in cancer metabolism

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 650-654

  Adekola, Kehinde ^a   Rosen, Steven T ^a   Shanmugam, Mala ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

cancer metabolism; glucose transporter; Warburg effect

Indexed keywords

ANTINEOPLASTIC AGENT; DEHYDROASCORBIC ACID; FASENTIN; FLUORODEOXYGLUCOSE F 18; GENISTEIN; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 5; HEXOKINASE; HEXOSE; IMATINIB; INSULIN; LACTATE DEHYDROGENASE; LACTIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PYRUVATE DEHYDROGENASE; RITONAVIR; STF 31; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; B CELL LYMPHOMA; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL LEVEL; CELL PROLIFERATION; COLORECTAL CARCINOMA; DIAGNOSTIC IMAGING; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ENDOCYTOSIS; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE EXPRESSION; GENE ISOLATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HEAD AND NECK CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; ISOTOPE LABELING; LARYNX CARCINOMA; LEIOMYOMA; LIVER CELL CARCINOMA; LUNG CANCER; MITOCHONDRIAL RESPIRATION; MYELOMA; NEUROBLASTOMA; NONHUMAN; ONCOGENE C MYC; ONCOGENE RAS; ONCOGENE SRC; OXIDATIVE PHOSPHORYLATION; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CARBOHYDRATE METABOLISM; GENISTEIN; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEASE INHIBITORS;

EID: 84868204401     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328356da72     Document Type: Review

References (45)

1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-1033.
2. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res 2002; 35:9-26.
3. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (glut) proteins in cancer. J Cell Physiol 2005; 202:654-662.
4. Krzeslak A, Wojcik-Krowiranda K, Forma E, et al. Expression of glut1 and glut3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res 2012; 18:721-728.
5. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11:325-337.
6. Shanmugam M, McBrayer SK, Qian J, et al. Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine. J Biol Chem 2009; 284:26816-26830.
7. Shanmugam M, McBrayer SK, Rosen ST. Targeting the warburg effect in hematological malignancies: from PET to therapy. Curr Opin Oncol 2009; 21:531-536.
8. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009; 121:29-40.
9. Mathupala SP, Ko YH, Pedersen PL. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 2010; 1797:1225-1230.
10. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011; 10:671-684.
11. Rodriguez-Enriquez S, Marin-Hernandez A, Gallardo-Perez JC, Moreno-Sanchez R. Kinetics of transport and phosphorylation of glucose in cancer cells. J Cell Physiol 2009; 221:552-559.
12. Marin-Hernandez A, Rodriguez-Enriquez S, Vital-Gonzalez PA, et al. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J 2006; 273:1975-1988.
13. Kaida H, Ishibashi M, Yuzuriha M, et al. Glucose transporter expression of an esophageal gastrointestinal tumor detected by F-18 FDG PET/CT. Clin Nucl Med 2010; 35:505-509.
14. Garcia Boy R, Knapp EM, Eisenhut M, et al. Enzymes/transporters. Handbook of experimental pharmacology 2008; 185 (Pt 2):131-143.
15. Hirose Y, Kaida H, Ishibashi M, et al. Glucose transporter expression of intraductal papilloma of the breast detected by fluorodeoxyglucose positron emission tomography. Jpn J Radiol 2011; 29:217-221.
16. Lee C, Raffaghello L, Brandhorst S, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 2012; 4:124ra127.
17. Augustin R. The protein family of glucose transport facilitators: it's not only about glucose after all. IUBMB Life 2010; 62:315-333.
18. Frolova AI, Moley KH. Glucose transporters in the uterus: an analysis of tissue distribution and proposed physiological roles. Reproduction 2011; 142:211-220.
19. Jun YJ, Jang SM, Han HL, et al. Clinicopathologic significance of glut1 expression and its correlation with apaf-1 in colorectal adenocarcinomas. World J Gastroenterol 2011; 17:1866-1873.
20. Luo XM, Zhou SH, Fan J.Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma. J Int Med Res 2010; 38:1885-1892.
21. Grabellus F, Nagarajah J, Bockisch A, et al. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 2012; 37:121-127.
22. Reinicke K, Sotomayor P, Cisterna P, et al. Cellular distribution of glut-1 and glut-5 in benign and malignant human prostate tissue. J Cell Biochem 2012; 113:553-562.
23. Sakashita M, Aoyama N, Minami R, et al. Glut1 expression in t1 and t2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer 2001; 37:204-209.
24. Fang J, Luo XM, Yao HT, et al. Expression of glucose transporter-1, hypoxiainducible factor-1alpha, phosphatidylinositol 3-kinase and protein kinase b (akt) in relation to [(18)f]fluorodeoxyglucose uptake in nasopharyngeal diffuse large b-cell lymphoma: a case report and literature review. J Int Med Res 2010; 38:2160-2168.
25. Basturk O, Singh R, Kaygusuz E, et al. Glut-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas 2011; 40:187-192.
26. Chan DA, Sutphin PD, Nguyen P, et al. Targeting glut1 and the warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 2011; 3:94-70.
27. Amann T, Hellerbrand C. Glut1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 2009; 13:1411-1427.
28. Carvalho KC, Cunha IW, Rocha RM, et al. Glut1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) 2011; 66:965-972.
29. McBrayer SK, Cheng JC, Singhal S, et al. Multiple myeloma exhibits novel dependence on glut4, glut8, and glut11: implications for glucose transporterdirected therapy. Blood 2012; 119:4686-4697.
30. Tarn C, Skorobogatko YV, Taguchi T, et al. Therapeutic effect of imatinib in gastrointestinal stromal tumors: Akt signaling dependent and independent mechanisms. Cancer Res 2006; 66:5477-5486.
31. Watanabe M, Naraba H, Sakyo T, Kitagawa T. DNA damage-induced modulation of glut3 expression is mediated through p53-independent extracellular signal-regulated kinase signaling in hela cells. Mol Cancer Res 2010; 8:1547-1557.
32. Kawauchi K, Araki K, Tobiume K, Tanaka N. P53 regulates glucose metabolism through an ikk-nf-kappab pathway and inhibits cell transformation. Nat Cell Biol 2008; 10:611-618.
33. Medina Villaamil V, Aparicio Gallego G, Valbuena Rubira L, et al. Fructose transporter glut5 expression in clear renal cell carcinoma. Oncol Rep 2011; 25:315-323.
34. Wuest M, Trayner BJ, Grant TN, et al. Radiopharmacological evaluation of 6-deoxy-6-[18f]fluoro-d-fructose as a radiotracer for pet imaging of glut5 in breast cancer. Nucl Med Biol 2011; 38:461-475.
35. Cheeseman C. Glut7: a new intestinal facilitated hexose transporter. Am J Physiol Endocrinol Metab 2008; 295:E238-E241.
36. Caulfield MJ, Munroe PB, O'Neill D, et al. Slc2a9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5:e197.
37. Porpaczy E, Bilban M, Heinze G, et al. Gene expression signature of chronic lymphocytic leukaemia with trisomy 12. Eur J Clin Invest 2009; 39:568-575.
38. Zhang W, Liu Y, Chen X, Bergmeier SC. Novel inhibitors of basal glucose transport as potential anticancer agents. Bioorg Med Chem Lett 2010; 20:2191-2194.
39. Wang D, Chu PC, Yang CN, et al. Development of a novel class of glucose transporter inhibitors. J Med Chem 2012; 55:3827-3836.
40. Velentzis LS, Woodside JV, Cantwell MM, et al. Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know. Eur J Cancer 2008; 44:1799-1806.
41. Horn-Ross PL, John EM, Lee M, et al. Phytoestrogen consumption and breast cancer risk in a multiethnic population: the Bay Area Breast Cancer Study. Am J Epidemiol 2001; 154:434-441.
42. Vera JC, Reyes AM, Carcamo JG, et al. Genistein is a natural inhibitor of hexose and dehydroascorbic acid transport through the glucose transporter, glut1. J Biol Chem 1996; 271:8719-8724.
43. Vera JC, Reyes AM, Velasquez FV, et al. Direct inhibition of the hexose transporter glut1 by tyrosine kinase inhibitors. Biochemistry (Mosc) 2001; 40:777-790.
44. Wood TE, Dalili S, Simpson CD, et al. A novel inhibitor of glucose uptake sensitizes cells to fas-induced cell death. Mol Cancer Ther 2008; 7:3546-3555.
45. Wardell SE, Ilkayeva OR, Wieman HL, et al. Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 2009; 23:388-401.